| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.15 | 0.0009 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.25 | 0.002 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.002 |